Retrospective comparison of patient outcomes on pacritinib versus ruxolitinib in patients with myelofibrosis and thrombocytopenia

Claire Harrison,Prithviraj Bose,Ruben Mesa,Aaron Gerds,Stephen Oh,Jean-Jacques Kiladijan,Valentin Garcia-Gutierrez,Alessandro Vannucchi,Christof Scheid,Marta Sobas,Srdan Verstovsek,Sarah Buckley,Karisse Roman-Torres,John Mascarenha

HemaSphere（2023）

引用 1|浏览4

暂无评分

摘要

PAC yielded higher response rates and a similar safety profile to lower-dose RUX in patients with MF who have moderate or severe thrombocytopenia. This study was supported by CTI BioPharma.

查看译文

关键词

patient outcomes comparison pacritinib,myelofibrosis,ruxolitinib,thrombocytopenia

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要